U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07300475) titled 'Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients' on Dec. 09.
Brief Summary: This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer immunotherapeutic (PCI) strategy with or without CD8-selective IL-2 mutein fusion protein in patients with triple negative breast cancer undergoing neoadjuvant chemoimmunotherapy.
Study Start Date: March 31, 2026
Study Type: INTERVENTIONAL
Condition:
Triple Negative Breast Cancer
Intervention:
DRUG: Paclitaxel
As part of the KEYNOTE 522 Regimen, paclitaxel is given intravenously (IV) with a dose 80 mg/m2 on...